AbbVie Reports the P-II (EMPOWER) Studies Data of Emraclidine for Treating Schizophrenia
Shots:
- The P-II EMPOWER-1 trial assessed 10 & 30mg while EMPOWER-2 evaluated 15 & 30mg of emraclidine vs PBO among schizophrenia patients having an acute exacerbation. Another 52wks. EMPOWER-3 OLE trial involved patients not experiencing acute psychotic symptom exacerbations
- Trial failed to achieve its 1EP of significantly improving PANSS total scores at wk.6. EMPOWER-1 showed LS mean change of -14.7 & -16.5 vs -13.5 in those having baseline PANSS of 97.6 & 97.9 vs 98.3; EMPOWER-2 depicted LS mean change of -18.5 & -14.2 vs -16.1 in those having baseline PANSS of 98.0 & 97.2 vs 97.4
- Emraclidine was well-tolerated with a safety similar to P-Ib; common AEs were headache, dry mouth & dyspepsia. Data analysis is underway to determine next steps
Ref: Abbvie | Image: Abbvie
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
